Qi Sun

Dr. Qi Sun


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2017 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
QSQi Sun
Qi Sun
JLJacqueline Lesperance
Jacqueline Lesperance
HWHiromi Wettersten
Hiromi Wettersten
ELElaine Luterstein
Elaine Luterstein
YDYoko S. DeRose
Yoko S. DeRose
JDJay S. Desgrosellier
Jay S. Desgrosellier
Breast cancer cells with stem cell properties are key contributors to metastatic disease, and there remains a need to better understand and target these cells in human cancers. Here, we identified rare stem-like cells in patients’ tumors characterized by low levels of the proapoptotic molecule p53-upregulated modulator of apoptosis (PUMA) and showed that these cells play a critical role in tumor progression that is independent of clinical subtype. A signaling axis consisting of the integrin αvβ3, Src kinase, and the transcription factor Slug suppresses PUMA in these cells, promoting tumor stemness. We showed that genetic or pharmacological disruption of αvβ3/Src signaling drives PUMA expression, specifically depleting these stem-like tumor cells; increases their sensitivity to apoptosis; and reduces pulmonary metastasis, with no effect on primary tumor growth. Taken together, these findings point to PUMA as a key vulnerability of stem-like cells and suggest that pharmacological upregulation of PUMA via Src inhibition may represent a strategy to selectively target these cells in a wide spectrum of aggressive breast cancers.

13 August 2020 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
QSQi Sun
Qi Sun
YSYukui Shang
Yukui Shang
FSFengkai Sun
Fengkai Sun
XDXiwen Dong
Xiwen Dong
JNJun Niu
Jun Niu
FLFanni Li
Fanni Li
The metastatic potential of colorectal cancer (CRC) is intensively promoted by the tumor microenvironment (TME) in a paracrine manner. As a pleiotropic inflammatory cytokine, Interleukin-6 (IL-6) is produced and involved in CRC, the same scenario where integrin αvβ6 also becomes upregulated. However, the relationship between IL-6 and integrin αvβ6 as well as their involvement in the crosstalk between CRC and TME remains largely unclear. In the present study, we demonstrated a positive correlation between the expression of IL-6 and integrin β6 in CRC samples. The mutually promotive interaction between CRC and TME was further determined by an indirect coculture system. CRC cells could augment the secretion of IL-6 from fibroblasts, which in return induced invasion and integrin β6 expression of CRC cells. Through the classic IL-6 receptor/STAT-3 signaling pathway, IL-6 mediated the upregulation of integrin β6, which was involved in the invasion and epithelial-mesenchymal transition of CRC cells induced by IL-6. Taken together, our results reveal a paracrine crosstalk between IL-6 signals originating from the TME and increased the integrin β6 level of CRC. IL-6 induces CRC invasion via upregulation of integrin β6 through the IL-6 receptor/STAT-3 signaling pathway. Combined inhibition of IL-6 along with integrin β6-targeted strategy may indicate new directions for antitumor strategies for CRC.

24 February 2022 in Cardiovascular Toxicology
Verified
Journal Article
Closed access
PDF file
HWHanxue Wu
Hanxue Wu
QSQi Sun
Qi Sun
SYShenglan Yuan
Shenglan Yuan
JWJiawei Wang
Jiawei Wang
FLFanni Li
Fanni Li
JXJiaxi Xu
Jiaxi Xu

29 March 2025 in Acta Biomaterialia
Verified
Journal Article
Closed access
YXYuhang Xu
Yuhang Xu
XXXiaoyu Xu
Xiaoyu Xu
YZYuan Zhao
Yuan Zhao
YTYaNing Tian
YaNing Tian
YMYubo Ma
Yubo Ma
QSQi Sun
Qi Sun

1 October 2020 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
FLFanni Li
Fanni Li
YSYukui Shang
Yukui Shang
FSFeiyu Shi
Feiyu Shi
LZLei Zhang
Lei Zhang
JYJun Yan
Jun Yan
JSJunjun She
Junjun She
Purpose: The development of esophageal squamous cell carcinoma (ESCC) is a complicated process in which cell adhesion and motility, mediated by integrins, are involved through connecting the cytoskeleton to extracellular matrix. Different mechanisms via which integrin β 6 participates in cancer invasion and metastasis have been described by numerous studies; however, the expression and clinical significance of integrin β 6 in ESCC remain unknown. Methods: To investigate the differential expression of integrin β 6 in ESCC, qPCR and immunohistochemistry assays were performed in 10 paired human samples. A total of 137 ESCC samples were further enrolled to evaluate the expression levels of integrin β 6 and its endocytic trafficking regulator HS1-associated protein X-1 (HAX-1), followed by the evaluation of their correlation with clinicopathological parameters. The overall survival was analyzed using the Kaplan–Meier method, with significant variables further evaluated by multivariate Cox regression analyses. Results: The expression of integrin β 6 was markedly increased in ESCC compared with matched adjacent normal tissues. Among the ESCC samples, positive expression of integrin β 6 was observed in 41.6% tumors, which was associated with histological differentiation, lymph node metastasis and TNM stage. High expression of HAX-1 was detected in 47.4% tumors, and there was a positive relationship between the expression levels of integrin β 6 and HAX-1. Furthermore, the expression of integrin β 6 and HAX-1 were independent unfavorable indicators for prognosis. Patients with positive integrin β 6 and high HAX-1 expression demonstrated worst outcomes. Conclusion: The present findings suggested the predictive value of integrin β 6 and HAX-1 as independent indicators of poor prognosis for patients with ESCC, both of which may contribute to the tumor proliferation and metastasis, leading to ESCC progression. Therefore, combined targeting of integrin β 6 and HAX-1 may provide a potential novel approach for the treatment of ESCC.

13 May 2018 in BioMed Research International
Verified
Journal Article
Open access
PDF file
QSQi Sun
Qi Sun
FLFanni Li
Fanni Li
SYSongyang Yu
Songyang Yu
XZXiang Zhang
Xiang Zhang
FSFeiyu Shi
Feiyu Shi
JSJunjun She
Junjun She
Hilar cholangiocarcinoma (HC) is a devastating malignancy that carries a poor overall prognosis. As a member of the AAA+ superfamily, Pontin becomes highly expressed in several malignant tumors, which contributes to tumor progression and influences tumor prognosis. In our research, Pontin expression in tumor specimens resected from 86 HC patients was detected by immunohistochemistry. Interestingly, high expression of Pontin was significantly associated with lymph node metastasis (p=0.011) and tumor node metastasis (TNM) stage (p=0.005). The Kaplan–Meier overall survival rate and multivariate analyses were performed to evaluate the prognosis of patients with HC. Patients with high Pontin expression had significantly poorer overall survival outcomes. Multivariate analyses found that Pontin was an independent prognostic factor (p=0.001). Moreover, bioinformatics analysis confirmed the increase in Pontin mRNA expression levels in cholangiocarcinoma tissues. In addition, in vitro experiments showed that Pontin expression was inhibited at the mRNA as well as protein levels after transfection with Pontin siRNA in human cholangiocarcinoma cell lines. Moreover, significant suppression of cell invasion was observed after the downregulation of Pontin. Taken together, the present study suggested that Pontin could act as a potential prognostic predictor, which might be a new valuable molecular candidate for the prevention and treatment of HC.